Table 3.
Treatment outcomes of non–ANT-based or ASP-based chemotherapy with or without radiotherapy in patients with ENKTCL
| Author | Total no. | Eligibility and stage | Study type | Chemotherapy regimen | RT no. (%) | OS % (y) | PFS % (y) |
|---|---|---|---|---|---|---|---|
| Early stage (newly diagnosed, n ≥ 30) | |||||||
| Yamaguchi et al7,8 | 33 | Newly, I: 22, II: 11 | Phase 1/2 | Concurrent DeVIC/RT | 33 (100) | 73 (5) | 67 (5) |
| Kim et al9 | 30 | Newly, I: 15, II: 15 | Phase 2 | Concurrent VIDP/RT | 30 (100) | 86.3 (3) | 85.2 (3) |
| Ke et al32 | 32 | Newly, I: 17, II: 15 | Phase 2 | Concurrent GDP/RT | 32 (100) | 87.5 (3) | 84.4 (3) |
| Kim et al12 | 30 | Newly, I: 21, II: 9 | Phase 2 | Concurrent VIDL/RT | 30 (100) | 60 (5) | 73 (5) |
| Kim et al13 | 44 | Newly, stage I-II | Phase 2 | Sequential IMEP/RT | 44 (100) | 66 (3) | 65 (3) |
| Tsai et al10 | 33 | Newly, I: 21, II: 12 | Phase 2 | Concurrent VIDP/RT | 33 (100) | 66 (5) | 60 (5) |
| Xu et al33 | 40 | Newly, stage I-II | Phase 2 | Sequential MESA/RT | 36 (90) | 92 (2) | 89.1 (2) |
| Qi et al14 | 40 | Newly, I: 27, II: 13, high-risk | Phase 2 | Sequential RT/GDP | 40 (100) | 82.1 (5) | 79.4 (5) |
| Oh et al34 | 62 | Newly, I: 46, II: 16 | Retrospective | Concurrent VIDP/MIDLE/RT | 13 (100) | 83.1 (3) | 77.1 (3) |
| Wang et al35 | 93 | Newly, stage I-II | Retrospective | Sequential GELOX/RT | 40 (100) | 78.9 (5) | 79 (5) |
| Sequential EPOCH/RT | 53 (100) | 50.4 (5) | 46.5 (5) | ||||
| Zang et al36 | 64 | Newly, I: 53, II: 11 | Retrospective | Sequential CHOP-L/SMILE/RT | Early (100) | 84.2 (3) | 74.3 (3) |
| Late (100) | 57.6 (3) | 55.9 (3) | |||||
| Tian et al37 | 72 | Newly, I: 54, II: 18 | Retrospective | Sequential GDP/RT | 72 (100) | 72 (5) | NR |
| Qi et al26 | 75 | Newly, I: 44, II: 31 | Retrospective | Sequential RT/GDP | 75 (100) | 79.4 (5) | NR |
| Hu et al38 | 94 | Newly, I: 19, II: 75 | Retrospective | Sequential LVD/RT | 94 (100) | 74.3 (5) | NR |
| Wei et al39 | 71 | Newly, stage I-II | Retrospective | Sequential EPOCHL/RT | 68 (96) | 65.3 (5) | NR |
| Kim et al21 | 344 | Newly, I: 228, II: 11, training cohort | Large multicenter | Non-ANT-based ± RT | NR | 75 (3) | 63 (3) |
| Li et al40 | 167 | Newly, stage I-II | Large multicenter | Sequential GELOXD/P-GEMOXD±RT | 142 (85) | 73 (3) | 72.8 (3) |
| Yamaguchi et al29 | 257 | Newly, stage I-II | Large multicenter | Concurrent DeVIC/RT: 150 | 150 (100) | 72 (5) | 61 (5) |
| Kwong et al30 | 244 | Newly, I: 170, II: 74 | Large multicenter | Concurrent non-ANT/RT Sequential non-ANT/RT | 54 (100) | 79.8 (5)* | 68.5 (5)* |
| 190 (100) | 74.4 (5)* | 52.2 (5)* | |||||
| Fox et al31 | 104 | Newly, I: 74, II: 30 | Large multicenter | Sequential non-ANT (62%) ±RT | 48/59 (81) | 59 m† | 46 m† |
| Present study | 1156 | Newly, I: 1438, II: 788 | Large multicenter | Sequential non-ANT ±RT | 977 (85) | 73.3 (5) | 64.0 (5) |
| Advanced stage (newly, relapsed or refractory) | |||||||
| Kim et al41 | 27 | Newly, IV: 27 | Phase 2 | SMILE (HSCT: 11) | 0 | 10.6 m† | 5.1 m† |
| Wang et al42 | 18 | Newly, III: 3, IV: 15 | Phase 2 | LVDP | 18 (100) | 23.0 m† | 10.5 m† |
| Ji et al43 | 21 | Newly, II: 1, III-IV: 20 | Retrospective | GLIDE (HSCT: 4) | 0 | 56 (3) | 35.8 (3) |
| Bi et al44 | 73 | Newly, III: 11, IV: 62 | Retrospective | L-ASP-based: 23 | 17 (27) | 38.3 (2) | 25.4 (2) |
| L-ASP absent: 46 | 22.7 (2) | 14.9 (2) | |||||
| Ding et al45 | 13 | R/R, III: 8, IV: 5 | Retrospective | MEDA | 8 (62) | 69.2 (1) | 61.5 (1) |
| Kim et al46 | 70 | Newly, III: 4, IV: 66 | Multicenter | L-IMEP: 22 | 0 | 36.6 m† | 10.1 m† |
| IMEP: 48 | 5.4 m† | 3.2 m† | |||||
| Yamaguchi et al29 | 101 | Newly, stage III-IV | Large multicenter | ASP based (70%) | 69 (68) | 24 (5) | NR |
| Fox et al31 | 49 | Newly, stage III-IV | Large multicenter | Non–ANT based | NR | 19 m† | 15 m† |
| Present study | 195 | Newly, III: 48, IV: 147 | Large multicenter | Non–ANT based | 74 (38) | 39.8 (5) | 30.1 (5) |
| Early and advanced stage (newly, relapsed or refractory) | |||||||
| Yamaguchi et al7 | 38 | R/R or newly, I-II: 11, III-IV: 27 | Phase 2 | SMILE (HSCT: 21) | NR | 55 (1) | 53 (1) |
| Jaccard et al15 | 19 | R/R, I-II: 12, III-IV: 7 | Phase 2 | AspaMetDex (ASCT: 5) | 1 (5) | 12.2 m† | 12.2 m† |
| Kwong et al16 | 87 | R/R 44, Newly, 43. I-II: 38, III-IV: 49 | Phase 2 | SMILE (HSCT: 24) | 19 (22) | 50 (5) | 64 (4) |
| Yong et al47 | 18 | Refractory, I-II2: 7, III-IV: 11 | Retrospective | L-ASP based | 18 (100) | 55.6 (5) | NR |
| Yong et al48 | 45 | R/R, I-II: 33, III-IV: 12 | Retrospective | LVD | 41 (91) | 66.9 (5) | NR |
| Zhou et al49 | 17 | R/R, I-II: 8, III-IV: 9 | Retrospective | DDGP | 4 (24) | 82.4 (1) | 64.7 (1) |
| Lin et al50 | 38 | Newly, I-II: 31, III-IV: 7 | Phase 2 | CHOP-L | 31 (82) | 80.1 (2) | 81 (2) |
| Guo et al51 | 55 | Newly, I-II: 45, III-IV: 10 | Retrospective | GOLD | 45 (82) | 74 (3) | 57 (3) |
| Wang et al52 | 98 | Newly, I-II: 77, III-IV: 21 | Retrospective | GELOX, P-Gemox | 77 (79) | 65.2 (3) | 57.0 (3) |
| Kim et al21 | 527 | Newly, I-II: 344, III-IV: 183 | Large multicenter | Non–ANT based (HSCT: 49) | 325 (62) | 59 (3) | 48 (3) |
| Yahaguchi et al29 | 358 | Newly, I-II: 257, III-IV: 101 | Large multicenter | Non–ANT based | 278 (78) | 56 (5) | 45 (5) |
| Fox et al31 | 166 | Newly, I-II: 104, III-IV: 49 | Large multicenter | Non–ANT based | 87/130 (67) | 59 m† | 20† |
| Present study | 1351 | Newly, I-II: 1156, III-IV: 195 | Large multicenter | Non–ANT based | 1051 (78) | 68.9 (5) | 59.5 (5) |
Estimated from the figures.
Median survival time (months).
ASCT, allogeneic stem cell transplant; AspaMetDex, l-ASP, methotrexate, and dexamethasone; CHOP-L, cyclophosphamide, doxorubicin, vincristine, prednisolone, and l-ASP; CT, chemotherapy; DDGP, GEM, pegaspargase, cisplatin, and dexamethasone; DeVIC, carboplatin, etoposide, ifosfamide, and dexamethasone; EPOCH, etoposide, vincristine, cyclophosphamide, doxorubicin, and prednisone; ESHAP, etoposide, steroid, high-dose Ara-C, and platinum; GDP, GEM, dexamethasone, and cisplatin; GELOX, GEM, oxaliplatin, and l-ASP; GLIDE, GEM, l-ASP, ifosfamide, dexamethasone, and etoposide; GOLD, GEM oxaliplatin, l-ASP, and dexamethasone; HSCT, hematopoietic stem cell transplant; IMEP, ifosfamide, methotrexate, etoposide, and prednisolone; L-ASP, l-ASP; L-IMEP, l-ASP, ifosfamide, methotrexate, etoposide, and prednisolone; LVD, l-ASP, vincristine, and dexamethasone; LVDP, l-ASP, etoposide, dexamethasone, and cisplatin; LVP, l-ASP, vincristine, and prednisolone; MEDA/MESA, methotrexate, etoposide, dexamethasone, and pegaspargase; MIDLE, methotrexate, etoposide, ifosfamide, mesna, and l-ASP; NR, not reported; P-Gemox, pegaspargase, GEM, and oxaliplatin; R/R, relapsed/refractory; RT, radiotherapy; SMILE, dexamethasone, methotrexate, ifosfamide, l-ASP, and etoposide; VIDL, etoposide, ifosfamide, cisplatin, and l-ASP; VIDP, etoposide, ifosfamide, cisplatin, and dexamethasone.